GTBP Accounts Payable vs Retained Earnings Analysis
GTBP Stock | USD 3.75 0.11 2.85% |
GT Biopharma financial indicator trend analysis is much more than just examining GT Biopharma latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether GT Biopharma is a good investment. Please check the relationship between GT Biopharma Accounts Payable and its Retained Earnings accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GT Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.
Accounts Payable vs Retained Earnings
Accounts Payable vs Retained Earnings Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of GT Biopharma Accounts Payable account and Retained Earnings. At this time, the significance of the direction appears to have pay attention.
The correlation between GT Biopharma's Accounts Payable and Retained Earnings is -0.73. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of GT Biopharma, assuming nothing else is changed. The correlation between historical values of GT Biopharma's Accounts Payable and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of GT Biopharma are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Accounts Payable i.e., GT Biopharma's Accounts Payable and Retained Earnings go up and down completely randomly.
Correlation Coefficient | -0.73 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Accounts Payable
An accounting item on the balance sheet that represents GT Biopharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of GT Biopharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Most indicators from GT Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into GT Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GT Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.At this time, GT Biopharma's Selling General Administrative is relatively stable compared to the past year. As of 05/31/2024, Issuance Of Capital Stock is likely to grow to about 10.2 M, while Sales General And Administrative To Revenue is likely to drop 2.17.
2023 | 2024 (projected) | Total Operating Expenses | 13.6M | 10.7M | Cost Of Revenue | 3.6K | 3.4K |
GT Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
GT Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
GT Biopharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 396K | 5.7M | 32.2M | 16.7M | 14.1M | 13.2M | |
Other Current Liab | 4.4M | 383K | 138K | 1.7M | 2.2M | 2.3M | |
Total Current Liabilities | 19.7M | 35.1M | 10.3M | 4.9M | 6.6M | 6.9M | |
Total Stockholder Equity | (19.1M) | (29.3M) | 21.9M | 11.7M | 7.5M | 7.1M | |
Property Plant And Equipment Net | 35K | 110K | 0.0 | 165K | 53K | 50.4K | |
Net Debt | 13.3M | 21.0M | (8.9M) | (5.5M) | (1.0M) | (970.0K) | |
Retained Earnings | (567.3M) | (595.6M) | (653.6M) | (674.5M) | (682.1M) | (648.0M) | |
Accounts Payable | 1.9M | 2.2M | 8.2M | 3.1M | 4.3M | 4.5M | |
Cash | 28K | 5.3M | 9.0M | 5.7M | 1.1M | 1.2M | |
Non Current Assets Total | 25.3M | 122K | 0.0 | 174K | 53K | 50.4K | |
Cash And Short Term Investments | 28K | 5.3M | 32.0M | 16.5M | 14.0M | 14.7M | |
Common Stock Total Equity | 50K | 51K | 70K | 52K | 46.8K | 44.5K | |
Common Stock Shares Outstanding | 112.8K | 146.2K | 938.5K | 1.1M | 1.3M | 1.3M | |
Liabilities And Stockholders Equity | 396K | 5.7M | 32.2M | 16.7M | 14.1M | 13.2M | |
Other Current Assets | 246K | 364K | 190K | 54K | 84K | 79.8K | |
Other Stockholder Equity | 548.1M | 566.3M | 673.2M | 686.2M | 689.5M | 724.0M | |
Total Liab | 19.7M | 35.1M | 10.3M | 5.0M | 6.6M | 7.1M | |
Property Plant And Equipment Gross | 35K | 110K | 0.0 | 165K | 53K | 50.4K | |
Total Current Assets | 274K | 5.7M | 32.2M | 16.6M | 14.1M | 14.8M | |
Common Stock | 70K | 52K | 1.1M | 33K | 1K | 950.0 | |
Short Long Term Debt Total | 10.8M | 13.4M | 26.3M | 174K | 58K | 55.1K | |
Short Term Debt | 10.8M | 13.4M | 26.3M | 110K | 58K | 55.1K | |
Net Tangible Assets | (13.7M) | (19.1M) | (29.3M) | 21.9M | 25.2M | 26.5M | |
Short Long Term Debt | 31K | 10.8M | 13.2M | 26.3M | 35.7K | 33.9K | |
Net Invested Capital | (5.9M) | (2.9M) | 21.9M | 11.7M | 7.5M | 7.1M | |
Net Working Capital | (19.4M) | (29.4M) | 21.9M | 11.6M | 7.4M | 7.8M | |
Capital Stock | 73K | 55K | 1.1M | 34K | 2K | 1.9K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GT Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.Note that the GT Biopharma information on this page should be used as a complementary analysis to other GT Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for GTBP Stock analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |
Is GT Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GT Biopharma. If investors know GTBP will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GT Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.45) | Return On Assets (0.54) | Return On Equity (1.05) |
The market value of GT Biopharma is measured differently than its book value, which is the value of GTBP that is recorded on the company's balance sheet. Investors also form their own opinion of GT Biopharma's value that differs from its market value or its book value, called intrinsic value, which is GT Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GT Biopharma's market value can be influenced by many factors that don't directly affect GT Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GT Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if GT Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GT Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.